XenoPort Revenue and Competitors
Estimated Revenue & Valuation
- XenoPort's estimated annual revenue is currently $27.5M per year.
- XenoPort's estimated revenue per employee is $241,553
Employee Data
- XenoPort has 114 Employees.
- XenoPort grew their employee count by 1% last year.
XenoPort's People
| Name | Title | Email/Phone |
|---|
XenoPort Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $46.2M | 221 | 16% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 91 | -10% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 16 | -6% | $114.3M | N/A |
#8 | $7.2M | 28 | -7% | N/A | N/A |
#9 | $13.7M | 51 | -9% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is XenoPort?
XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in the United States by XenoPort. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in Japan by Astellas Pharma Inc. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates includes potential treatments for patients with Parkinson's disease, relapsing-remitting multiple sclerosis and psoriasis.
keywords:N/A
N/A
Total Funding
114
Number of Employees
$27.5M
Revenue (est)
1%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $51.2M | 114 | 4% | N/A |
#2 | $37.6M | 114 | 10% | N/A |
#3 | $30.8M | 114 | 43% | N/A |
#4 | $30.4M | 114 | 0% | N/A |
#5 | $20M | 114 | 6% | N/A |